Smartleaf Asset Management LLC Has $60,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 512.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,905 shares of the biopharmaceutical company’s stock after buying an additional 1,594 shares during the period. Smartleaf Asset Management LLC’s holdings in TG Therapeutics were worth $60,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares during the period. Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter worth $75,000. GAMMA Investing LLC boosted its position in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the period. KBC Group NV boosted its position in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,092 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in TG Therapeutics during the third quarter valued at $111,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $39.23 on Tuesday. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $40.31. The business has a 50-day moving average of $31.23 and a two-hundred day moving average of $28.67. The stock has a market capitalization of $6.16 billion, a P/E ratio of -392.26 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $40.67.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.